2023年8月2日,

分享鏈接:https://1lo。有限公司/ n2MrL IP Group plc)(經度:IPO),投資於突破性的科學和創新潛力的公司創造一個更好的未來,已經宣布其財務結果截至2023年6月30日的六個月。半年2023強調投資組合資金充足,繼續在主題重大進展&公司·投資組合公司資金充足;投資組合籌集的資金總額約£300 (HY22: c。£350 m;FY22:£10億)包括量子運動(£42米),AccelerComm(£22米),OXCCU(£18米),駐軍(£16米)和Mixergy(£9米)·隻有我們的投資組合價值的16%需要籌集資金在2024年下半年之前·私人投資組合公司一輪融資估值仍然強勁,86%的14個組合融資輪在以上時期發生之前完成一輪融資估值·健康未來(生命科學):Istesso的2 b階段試驗導致藥物在風濕性關節炎MBS2320繼續招募計劃,仍將於2024年H1宣讀。批準收到額外的2期臨床試驗開始在特發性肺纖維化(IPF)在2023年H2。組完成了£15 m進一步投資和£10 m承諾充分基金兩個試驗。Pulmocide -招聘正在進行三期療效研究·Tech-enriched未來(Deeptech): Featurespace,駐軍和Ultraleap收入都會在H1,實現兩位數增長的重要籌資完成量子運動,AccelerComm &加裏森·再生未來(Cleantech):雄厚的技術進步在Hysata,關鍵裏程碑,觸發釋放第二筆係列的資金,OXCCU完成£18 m係列融資由清潔能源企業強勁的資產負債表保持·強勁的資產負債表和流動性支持新的和後續的投資組合與現金和存款總額在2023年6月30日的£250.0米(HY22:£235.7 m;FY22:£241.5米);總潛在的流動性包括引用的股票超過£450 m·現金收益與預期一致£32.2 m,第二部分主要從考慮出售WaveOptics (HY22:£2.1 m; FY22 £28.1m) · Investment into portfolio maintained: £59.8m into 23 companies across all three thematic areas (HY22: £52m; FY22: £93.5m) including significant allocation to Istesso (£15.0m) · Loss in the period of £54.5m (HY22: Loss of £309.8m; FY22: Loss of £344.5m), partly driven by a reduction in the value of Oxford Nanopore, which reduced by £27.8m, and negative portfolio foreign exchange movements of £11.2m (i) Note 12 details the Alternative Performance Measures (“APM”) (ii) Amount shown for FY 2022 is total dividend including final dividend approved and paid in 2023 Greg Smith, Chief Executive of IP Group, said: “IP Group is a long-term investor in breakthrough science and innovation companies that are addressing many of the world’s unmet needs and, while the current economic environment remains challenging, I am pleased with portfolio progress in the period. The successful raising of more than £300m of financing by our companies in the first half, including £60m from the Group, is testament to their quality. The Group has maintained its financial strength during the period, the result of £32m cash realisations and having taken pre-emptive action in light of the challenging investment environment. This financial strength was highlighted as a strategic asset as our portfolio navigated events such as the failure of Silicon Valley Bank. We have also continued our approach of dedicating a proportion of all cash realisations to supporting capital returns for shareholders through an interim dividend. The opportunity for value creation in our portfolio remains compelling. Double-digit revenue growth in our largest deeptech and healthcare companies is evidence of continued strong demand for their products and services. Our therapeutics portfolio includes twelve companies with products in clinical trials, seven of which are targeting key inflection points in the next 18 months. Breakthrough cleantech businesses, such as Hysata, have delivered technical milestones and commercial demand. The Group is well-positioned to support these businesses and deliver strong, impactful returns for all stakeholders over time.“ Find more news, interviews, share price & company profile here for: Good news travels fast (but only if you make that happen). Share on: Forum friendly shortlink: https://1lo.co/n2MrL